[go: up one dir, main page]

HUP1400510A1 - Gyógyászati TNFalfa ellenes antitest készítmény - Google Patents

Gyógyászati TNFalfa ellenes antitest készítmény

Info

Publication number
HUP1400510A1
HUP1400510A1 HU1400510A HUP1400510A HUP1400510A1 HU P1400510 A1 HUP1400510 A1 HU P1400510A1 HU 1400510 A HU1400510 A HU 1400510A HU P1400510 A HUP1400510 A HU P1400510A HU P1400510 A1 HUP1400510 A1 HU P1400510A1
Authority
HU
Hungary
Prior art keywords
antibody formulation
pharmaceutical anti
tnfalpha antibody
tnfalpha
pharmaceutical
Prior art date
Application number
HU1400510A
Other languages
English (en)
Inventor
Jozsef Lazar
Marcell Olajos
Janos Varga
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Priority to HU1400510A priority Critical patent/HUP1400510A1/hu
Priority to PL15808356T priority patent/PL3212667T3/pl
Priority to DE202015009509.7U priority patent/DE202015009509U1/de
Priority to DE202015009619.0U priority patent/DE202015009619U1/de
Priority to EP18190279.2A priority patent/EP3428189A1/en
Priority to PT15808356T priority patent/PT3212667T/pt
Priority to DK15808356.8T priority patent/DK3212667T3/en
Priority to EP15808356.8A priority patent/EP3212667B1/en
Priority to SI201530450T priority patent/SI3212667T1/sl
Priority to DE18190279.2T priority patent/DE18190279T1/de
Priority to MX2017005575A priority patent/MX2017005575A/es
Priority to DE202015009016.8U priority patent/DE202015009016U1/de
Priority to ES15808356T priority patent/ES2703586T3/es
Priority to US15/519,631 priority patent/US20170252437A1/en
Priority to BR112017009021A priority patent/BR112017009021A2/pt
Priority to RS20181458A priority patent/RS58172B1/sr
Priority to LTEP15808356.8T priority patent/LT3212667T/lt
Priority to TR2018/16518T priority patent/TR201816518T4/tr
Priority to PCT/EP2015/074986 priority patent/WO2016066688A1/en
Priority to CA2989930A priority patent/CA2989930A1/en
Priority to HUE15808356A priority patent/HUE040621T2/hu
Publication of HUP1400510A1 publication Critical patent/HUP1400510A1/hu
Priority to CY181101218T priority patent/CY1120937T1/el
Priority to HRP20182006TT priority patent/HRP20182006T1/hr
Priority to US17/222,261 priority patent/US20220016244A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU1400510A 2014-10-28 2014-10-28 Gyógyászati TNFalfa ellenes antitest készítmény HUP1400510A1 (hu)

Priority Applications (24)

Application Number Priority Date Filing Date Title
HU1400510A HUP1400510A1 (hu) 2014-10-28 2014-10-28 Gyógyászati TNFalfa ellenes antitest készítmény
ES15808356T ES2703586T3 (es) 2014-10-28 2015-10-28 Formulación farmacéutica de anticuerpos anti-TNF alfa
DE202015009016.8U DE202015009016U1 (de) 2014-10-28 2015-10-28 Pharmazeutische anti-TNFα Antikörperformulierung
DE202015009619.0U DE202015009619U1 (de) 2014-10-28 2015-10-28 Pharmazeutische anti-TNFα Antikörperformulierung
EP18190279.2A EP3428189A1 (en) 2014-10-28 2015-10-28 Pharmaceutical anti-tnf-alpha antibody formulation
PT15808356T PT3212667T (pt) 2014-10-28 2015-10-28 Formulação farmacêutica de anticorpo anti-tnf-alfa
DK15808356.8T DK3212667T3 (en) 2014-10-28 2015-10-28 PHARMACEUTICAL ANTI-TNF-ALPHA ANTIBODY FORMULATION
DE202015009509.7U DE202015009509U1 (de) 2014-10-28 2015-10-28 Pharmazeutische anti-TNFα Antikörperformulierung
SI201530450T SI3212667T1 (sl) 2014-10-28 2015-10-28 Farmacevtska formulacija protiteles anti-tnf-alfa
DE18190279.2T DE18190279T1 (de) 2014-10-28 2015-10-28 Pharmazeutische anti-tnf-alpha-antikörperformulierung
MX2017005575A MX2017005575A (es) 2014-10-28 2015-10-28 Formulacion farmaceutica de anticuerpos anti-tnf alfa.
PL15808356T PL3212667T3 (pl) 2014-10-28 2015-10-28 Farmaceutyczny preparat przeciwciał przeciwko tnf-alfa
EP15808356.8A EP3212667B1 (en) 2014-10-28 2015-10-28 Pharmaceutical anti-tnf-alpha antibody formulation
TR2018/16518T TR201816518T4 (tr) 2014-10-28 2015-10-28 Farmasötik anti-tnf-alfa antikor formülasyonu.
BR112017009021A BR112017009021A2 (pt) 2014-10-28 2015-10-28 formulação farmacêutica de anticorpo anti-tnfa
RS20181458A RS58172B1 (sr) 2014-10-28 2015-10-28 Farmaceutska formulacija anti-tnf-alfa antitela
LTEP15808356.8T LT3212667T (lt) 2014-10-28 2015-10-28 Farmacinė anti-tnf-alfa antikūnų kompozicija
US15/519,631 US20170252437A1 (en) 2014-10-28 2015-10-28 Pharmaceutical anti-tnf-alpha antibody formulation
PCT/EP2015/074986 WO2016066688A1 (en) 2014-10-28 2015-10-28 Pharmaceutical anti-tnf-alpha antibody formulation
CA2989930A CA2989930A1 (en) 2014-10-28 2015-10-28 Pharmaceutical anti-tnf.alpha. antibody formulation
HUE15808356A HUE040621T2 (hu) 2014-10-28 2015-10-28 Gyógyászati TNFalfa ellenes antitest készítmény
CY181101218T CY1120937T1 (el) 2014-10-28 2018-11-19 Φαρμακευτικη μορφοποιηση αντισωματος anti-tnf-αλφα
HRP20182006TT HRP20182006T1 (hr) 2014-10-28 2018-11-29 Farmaceutski pripravak anti-tnf-alfa antitijela
US17/222,261 US20220016244A1 (en) 2014-10-28 2021-04-05 Pharmaceutical anti-tnf-alpha antibody formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1400510A HUP1400510A1 (hu) 2014-10-28 2014-10-28 Gyógyászati TNFalfa ellenes antitest készítmény

Publications (1)

Publication Number Publication Date
HUP1400510A1 true HUP1400510A1 (hu) 2016-05-30

Family

ID=89991627

Family Applications (2)

Application Number Title Priority Date Filing Date
HU1400510A HUP1400510A1 (hu) 2014-10-28 2014-10-28 Gyógyászati TNFalfa ellenes antitest készítmény
HUE15808356A HUE040621T2 (hu) 2014-10-28 2015-10-28 Gyógyászati TNFalfa ellenes antitest készítmény

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15808356A HUE040621T2 (hu) 2014-10-28 2015-10-28 Gyógyászati TNFalfa ellenes antitest készítmény

Country Status (18)

Country Link
US (2) US20170252437A1 (hu)
EP (2) EP3212667B1 (hu)
BR (1) BR112017009021A2 (hu)
CA (1) CA2989930A1 (hu)
CY (1) CY1120937T1 (hu)
DE (4) DE202015009619U1 (hu)
DK (1) DK3212667T3 (hu)
ES (1) ES2703586T3 (hu)
HR (1) HRP20182006T1 (hu)
HU (2) HUP1400510A1 (hu)
LT (1) LT3212667T (hu)
MX (1) MX2017005575A (hu)
PL (1) PL3212667T3 (hu)
PT (1) PT3212667T (hu)
RS (1) RS58172B1 (hu)
SI (1) SI3212667T1 (hu)
TR (1) TR201816518T4 (hu)
WO (1) WO2016066688A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
MX2018009341A (es) 2016-02-03 2019-05-15 Oncobiologics Inc Formulaciones tamponadas para una mayor estabilidad de anticuerpos.
SI3479819T1 (sl) * 2016-06-30 2024-06-28 Celltrion Inc. Stabilen tekoči farmacevtski pripravek
HUP1600456A2 (en) 2016-07-19 2018-01-29 Richter Gedeon Nyrt Novel cell-based tnf-alpha binding assay
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
AU2018236651B2 (en) * 2017-03-16 2020-12-10 Lg Chem, Ltd. Liquid formulation of anti-TNF alpha antibody
WO2018184693A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
EA201900360A1 (ru) * 2017-12-29 2019-12-30 Закрытое Акционерное Общество "Биокад" ВОДНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА К ФНОα
EP3852842A2 (en) * 2018-09-20 2021-07-28 Teva Pharmaceuticals International GmbH Injection spring for aged prefilled syringe and auto injector
BR112021013497A2 (pt) * 2019-01-11 2021-09-14 Samsung Bioepis Co., Ltd. Composição farmacêutica compreendendo anticorpo, dispositivo compreendendo o mesmo e uso do mesmo
CA3169901A1 (en) * 2020-03-13 2021-09-16 Mi Gyeong Kim Pharmaceutical liquid composition having increased stability
DE102020129648A1 (de) 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung
KR20240135660A (ko) * 2022-01-27 2024-09-11 얀센 바이오테크 인코포레이티드 향상된 단백질 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9715219B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Vetor recombinante de expressão, e célula hospedeira procariótica.
FI20021199L (fi) 2002-06-19 2003-12-20 Kemira Growhow Oy Menetelmä tuotantoa rajoittavien paikkakohtaisten kasvutekijöiden analysoimiseksi
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
JP2013520476A (ja) * 2010-02-26 2013-06-06 ノヴォ ノルディスク アー/エス 安定な抗体含有組成物
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
EP2807190B1 (en) * 2012-01-23 2018-12-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
SG10201609982PA (en) 2012-03-07 2017-01-27 Cadila Healthcare Ltd Pharmaceutical formulations of tnf-alpha anitbodies
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
TW202042841A (zh) 2012-09-07 2020-12-01 美商柯赫勒斯生物科學有限公司 阿達木單抗(adalimumab)之穩定水性調配物
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
JP2016505633A (ja) * 2013-01-24 2016-02-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited TNFα抗原結合性タンパク質
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény

Also Published As

Publication number Publication date
HRP20182006T1 (hr) 2019-01-25
US20220016244A1 (en) 2022-01-20
EP3428189A1 (en) 2019-01-16
LT3212667T (lt) 2018-12-10
BR112017009021A2 (pt) 2018-02-06
WO2016066688A1 (en) 2016-05-06
DE202015009619U1 (de) 2018-08-29
PT3212667T (pt) 2018-12-20
RS58172B1 (sr) 2019-03-29
DE202015009016U1 (de) 2016-06-24
EP3212667B1 (en) 2018-09-19
EP3212667A1 (en) 2017-09-06
SI3212667T1 (sl) 2018-11-30
TR201816518T4 (tr) 2018-11-21
DE18190279T1 (de) 2019-07-11
DE202015009509U9 (de) 2018-05-30
US20170252437A1 (en) 2017-09-07
CY1120937T1 (el) 2019-12-11
CA2989930A1 (en) 2016-05-06
DE202015009509U1 (de) 2018-01-18
HUE040621T2 (hu) 2019-03-28
PL3212667T3 (pl) 2019-02-28
MX2017005575A (es) 2017-09-01
DK3212667T3 (en) 2018-12-03
ES2703586T3 (es) 2019-03-11

Similar Documents

Publication Publication Date Title
IL270954A (en) Pharmaceutical compounds
HRP20182006T1 (hr) Farmaceutski pripravak anti-tnf-alfa antitijela
IL250363A0 (en) Stable formulation of anti-il-4r-alpha antibody
IL248802B (en) Antibody formulation
GB201404922D0 (en) Pharmaceutical compounds
ZA201701461B (en) Antibody formulations
GB201416513D0 (en) Pharmaceutical compounds
SI3256154T1 (sl) Farmacevtska formulacija, ki obsega protitelo
GB201417707D0 (en) Pharmaceutical compounds
HRP20181406T1 (hr) Farmaceutski dozni oblici
GB201508022D0 (en) Pharmaceutical compounds
GB201415526D0 (en) Antibody Formulations
GB201415298D0 (en) Antibody Formulations
GB201416969D0 (en) Pharmaceutical compounds
GB201416968D0 (en) Pharmaceutical compounds
GB201416627D0 (en) Pharmaceutical compounds
GB201416625D0 (en) Pharmaceutical compounds
GB201416622D0 (en) Pharmaceutical compounds
GB201407741D0 (en) Novel drug formulation
GB201404896D0 (en) Pharmaceutical compounds
GB201402278D0 (en) Pharmaceutical compounds
GB201402013D0 (en) Pharmaceutical compounds
GB201400951D0 (en) Novel drug formulation
GB201401478D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished